Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer

<p>Purpose: Preclinically, AKT kinase inhibition restores drug sensitivity in platinum-resistant tumors.Here the pan-AKT kinase inhibitor afuresertib was given in combination with paclitaxel and carboplatin (PC) in patients with recurrent platinum-resistant epithelial ovarian cancer (PROC) and...

Full description

Bibliographic Details
Main Authors:	Blagden, S, Hamilton, A, Mileshkin, L, Wong, S, Michael, A, Hall, M, Goh, J, Lisyanskaya, A, Desilvio, M, Frangou, E, Stronach, E, Gopalakrishna, P, Meniawy, T, Gabra, H
Format:	Journal article
Language:	English
Published:	American Association for Cancer Research 2018

Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer

Similar Items